MasimoNASDAQ: MASI

Apple convinced a federal jury on Friday that health monitoring tech company Masimo's smartwatches infringe two of its design patents.

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the “Board”), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, “We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

As of Oct. 10, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Masimo said on Wednesday that Joe Kiani has decided to resign as CEO, days after shareholders voted to remove him from the company's board.

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Activist investor Politan won the two board seats it was seeking at Masimo, defeating founder Joe Kiani and another director at the shareholder vote. Politan nominees Darlene Solomon and Bill Jellison will join two others who were added to the board in a prior proxy fight.

Masimo Corp shareholders elected both director candidates proposed by veteran activist investor Quentin Koffey's hedge fund Politan Capital Management, in one of the most contentious boardroom battles of the year.